Provided by Tiger Trade Technology Pte. Ltd.

OCUMENSION-B

5.170
-0.130-2.45%
Volume:149.00K
Turnover:770.30K
Market Cap:4.21B
PE:-22.16
High:5.210
Open:5.160
Low:5.130
Close:5.300
52wk High:10.940
52wk Low:4.040
Shares:815.00M
HK Float Shares:815.00M
Volume Ratio:0.32
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.233
ROE:-3.45%
ROA:-1.93%
PB:1.00
PE(LYR):-22.16
PS:3.87

Loading ...

Delisting Doesn't Halt Claims! Investors in Poly Pharm (300630) File Another Court Case

Deep News
·
Aug 26

Novartis Secures New Chinese Approval for Key Radiopharmaceutical Therapy

Stock News
·
Aug 26

Shenyang Cracks Down on Illegal Veterinary Drug Sales: Two Stores Under Investigation

Deep News
·
Aug 24

Ascletis Pharma-B Warns of 263.5% Surge in Interim Loss to Roughly RMB 319.7 Million

Stock News
·
Aug 21

Huiyu Pharma's Aesthetic Medicine Expansion Stalls: Subsidiary Insolvency and Funding Model Expose Multiple Hazards

Deep News
·
Aug 21

Historic mRNA Cancer Vaccine Breakthrough Sends Pharmaceutical Stocks Soaring on US, A-share, and HK Markets

Deep News
·
Aug 20

BAIYUNSHAN PH Secures Regulatory Approval for Citicoline Sodium Injection New Dosage Strengths

Stock News
·
Aug 19

Penalty Finalized for Nanxin Pharmaceutical Over Disclosure Violations, Affected Investors Invited to Register Claims

Deep News
·
Aug 19

China's AI-Driven Drug Discovery Sector Poised for Clinical Breakthroughs and Commercial Growth, Analyst Says

Stock News
·
Aug 19

Zejing Pharma Seeks Hong Kong Listing After Turning Profitable, But Earnings Quality Raises Questions

Deep News
·
Aug 17

17 Drugmakers Announce Major Executive Reshuffles in Half a Month

Deep News
·
Aug 17

BAIYUNSHAN PH Subsidiary Secures Pharmaceutical Registration Certificate from Macau Health Regulator

Stock News
·
Aug 17

Fictitious Profits Equated to 157% of Total Reported Income: A 2023 Loss Was Masked as Gains for This Company, Affected Investors May Be Eligible for Claims

Deep News
·
Aug 17

Penalty on Nanyangxin Pharmaceutical Fuels Ongoing Investor Claims

Deep News
·
Aug 14

Ocumension Therapeutics Sets 28 August Board Meeting to Review 1H 2026 Results and Potential Interim Dividend

Bulletin Express
·
Aug 14

Ocumension Therapeutics Schedules Board Meeting to Review Interim Results, Consider Dividend

Reuters
·
Aug 14

Zelgen Biopharma Makes Second Attempt at Hong Kong IPO Amid Insider Selling and Related-Party Acquisition Concerns

Deep News
·
Aug 14

Listing Update: Suzhou Zelgen Biopharmaceuticals Files Again for Hong Kong IPO

Stock News
·
Aug 13

Hong Kong Stock Movers: METIS TECHBIO-P Surges Over 7% Again, Accumulating Nearly 30% Gains Since Early August, Leading AI Drug Discovery Sector for Consecutive Days

Stock News
·
Aug 11

Ascletis-B Launches Two Phase 1 Obesity Studies in the United States

Stock News
·
Aug 10